Clinical Trial: NCT02492568
Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | The Netherlands Cancer Institute |
| Information Provided By: | The Netherlands Cancer Institute |
| Last Update Posted: | 2020-08-17 |
Study Overview
Brief Summary
To evaluate the increase in Overall Response Rate (ORR) in the pembrolizumab alone arm compared to the pembrolizumab after SBRT arm at 12 weeks
Official Title
Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: pembrolizumab
- Radiation: Stereotactic Body Radiation Therapy
Other Study ID Numbers
- M14PRT
- 2014-003935-20
- NL51468.031.14
- 2014
Start Date
2015-07
Primary Completion Date (Actual)
2018-06
Study Completion Date (Actual)
2018-06
Enrollment (Actual)
92
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | The Netherlands Cancer Institute |
| Information Provided By: | The Netherlands Cancer Institute |
| Last Update Posted: | 2020-08-17 |
Study Overview
Brief Summary
To evaluate the increase in Overall Response Rate (ORR) in the pembrolizumab alone arm compared to the pembrolizumab after SBRT arm at 12 weeks
Official Title
Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: pembrolizumab
- Radiation: Stereotactic Body Radiation Therapy
Other Study ID Numbers
- M14PRT
- 2014-003935-20
- NL51468.031.14
- 2014
Start Date
2015-07
Primary Completion Date (Actual)
2018-06
Study Completion Date (Actual)
2018-06
Enrollment (Actual)
92
Study Type
Interventional
Phase
Phase 2